The Role of Next-Generation Sequencing in Patients With Neuroendocrine Tumors

A manageable safety profile and survival benefit was observed across patient groups with somatostatin receptor–positive GEP-NETs.

Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.

Anna Greene, PhD, highlights the NETRF’s role as the largest funder of NET research, their current research funding opportunities, and its commitment to patient support.

Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.

Phase 3 data show that ITM-11 produced favorable safety results among patients with gastroenteropancreatic neuroendocrine tumors.

A phase 2 trial revealed survival with ramucirumab plus somatostatin was consistent with other VEGF pathways in treating advanced neuroendocrine tumors.